Current:Home > FinanceWorld's first gene therapy for sickle cell and thalassemia approved in the U.K.-Angel Dreamer Wealth Society D1 Reviews & Insights
World's first gene therapy for sickle cell and thalassemia approved in the U.K.
View Date:2024-12-23 20:08:35
Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K.
In a statement on Thursday, the Medicines and Healthcare Regulatory Agency said it approved Casgevy, the first medicine licensed using the gene editing tool CRISPR, which won its makers a Nobel Prize in 2020.
Casgevy — made by the Boston-based Vertex Pharmaceuticals (Europe) Ltd. and CRISPR Therapeutics — was approved by the agency for the treatment for patients with sickle cell disease and thalassemia who are 12 years old and over.
To date, bone marrow transplants, extremely arduous procedures that come with very unpleasant side effects, have been the only long-lasting treatment.
"The future of life-changing cures resides in CRISPR based (gene-editing) technology," said Dr. Helen O'Neill of University College London.
"The use of the word 'cure' in relation to sickle cell disease or thalassemia has, up until now, been incompatible," she said in a statement, calling the MHRA's approval of gene therapy "a positive moment in history."
Both sickle cell disease and thalassemia are caused by mistakes in the genes that carry hemoglobin, the protein in red blood cells that carry oxygen.
In people with sickle cell — which is particularly common in people with African or Caribbean heritage — a genetic mutation causes the cells to become crescent-shaped, which can block blood flow and cause excruciating pain, organ damage, stroke and other problems.
In people with thalassemia, the genetic mutation can cause severe anemia. Patients typically require blood transfusions every few weeks, and injections and medicines for their entire life. Thalassemia predominantly affects people of South Asian, Southeast Asian and Middle Eastern heritage.
The new medicine, Casgevy, works by targeting the problematic gene in a patient's bone marrow stem cells so that the body can make properly functioning hemoglobin.
Patients first receive a course of chemotherapy, before doctors take stem cells from the patient's bone marrow and use genetic editing techniques in a laboratory to fix the gene. The cells are then infused back into the patient for a permanent treatment. Patients must be hospitalized at least twice — once for the collection of the stem cells and then to receive the altered cells.
Britain's regulator said its decision to authorize the gene therapy for sickle cell disease was based on a study done on 29 patients, of whom 28 reported having no severe pain problems for at least one year after being treated. In the study for thalassemia, 39 out of 42 patients who got the therapy did not need a red blood cell transfusion for at least a year afterward.
Gene therapy treatments can cost millions of dollars and experts have previously raised concerns that they could remain out of reach for the people who would benefit most.
Last year, Britain approved a gene therapy for a fatal genetic disorder that had a list price of £2.8 million ($3.5 million). England's National Health Service negotiated a significant confidential discount to make it available to eligible patients.
Vertex Pharmaceuticals said it had not yet established a price for the treatment in Britain and was working with health authorities "to secure reimbursement and access for eligible patients as quickly as possible."
In the U.S., Vertex has not released a potential price for the therapy, but a report by the nonprofit Institute for Clinical and Economic Review said prices up to around $2 million would be cost-effective. By comparison, research earlier this year showed medical expenses for current sickle cell treatments, from birth to age 65, add up to about $1.6 million for women and $1.7 million for men.
Medicines and treatments in Britain must be recommended by a government watchdog before they are made freely available to patients in the national health care system.
Casgevy is currently being reviewed by the U.S. Food and Drug Administration; the agency is expected to make a decision early next month, before considering another sickle cell gene therapy.
Millions of people around the world, including about 100,000 in the U.S., have sickle cell disease. It occurs more often among people from places where malaria is or was common, like Africa and India, and is also more common in certain ethnic groups, such as people of African, Middle Eastern and Indian descent. Scientists believe being a carrier of the sickle cell trait helps protect against severe malaria.
Dr. Jon LaPook has reported on another effort to harness gene therapy to cure sickle cell disease. Watch that story in the video below:
- In:
- Sickle Cell Disease
- Chemotherapy
- Britain
- United Kingdom
- Thalassemia
- CRISPR
veryGood! (689)
Related
- 1 million migrants in the US rely on temporary protections that Trump could target
- From fugitive to shackled prisoner, ‘Fat Leonard’ lands back in US court and could face more charges
- Toyota recalls 1 million Toyota and Lexus vehicles because air bag may not deploy properly
- Philadelphia news helicopter crew filmed Christmas lights in New Jersey before fatal crash
- Elena Rose has made hits for JLo, Becky G and more. Now she's stepping into the spotlight.
- People's Choice Country Awards 2024 will return to Nashville's Grand Ole Opry House
- Russia’s foreign minister tours North Africa as anger toward the West swells across the region
- Extreme heat represents a new threat to trees and plants in the Pacific Northwest
- Georgia's humbling loss to Mississippi leads college football winners and losers for Week 11
- A train in Slovenia hits maintenance workers on the tracks. 2 were killed and 4 others were injured
Ranking
- Brush fire erupts in Brooklyn's iconic Prospect Park amid prolonged drought
- Who is Netflix's 'Rebel Moon' star? Former Madonna dancer Sofia Boutella takes the cape
- Federal judge blocks California law that would ban carrying firearms in most public places
- Philadelphia news helicopter crew filmed Christmas lights in New Jersey before fatal crash
- Repair Hair Damage In Just 90 Seconds With This Hack from WNBA Star Kamilla Cardoso
- Extreme heat represents a new threat to trees and plants in the Pacific Northwest
- 14 people injured, hundreds impacted in New York City apartment fire, officials say
- Ex-NBA player allegedly admitted to fatally strangling woman in Las Vegas, court documents show
Recommendation
-
Pennsylvania House Republicans pick new floor leader after failing to regain majority
-
Pacific storm dumps heavy rains, unleashes flooding in California coastal cities
-
Authorities return restored golden crosses to the domes of Kyiv’s St Sophia Cathedral
-
U.S. helps negotiate cease-fire for Congo election as world powers vie for access to its vital cobalt
-
What that 'Disclaimer' twist says about the misogyny in all of us
-
Science says declining social invites is OK. Here are 3 tips for doing it
-
UEFA, FIFA 'unlawful' in European Super League blockade. What this means for new league
-
This golden retriever is nursing 3 African painted dog pups at a zoo because their own mother wouldn't care for them